J Cancer 2016; 7(13):1798-1803. doi:10.7150/jca.15618 This issue Cite

Research Paper

Plasma Circulating Cell-free DNA Integrity as a Promising Biomarker for Diagnosis and Surveillance in Patients with Hepatocellular Carcinoma

Ao Huang1,#, Xin Zhang1,#, Shao-Lai Zhou1, Ya Cao2, Xiao-Wu Huang1, Jia Fan1,3, Xin-Rong Yang1✉, Jian Zhou1, 4✉

1. Liver Surgery Department, Liver Cancer Institute, Zhongshan Hospital, Fudan University
Key Laboratory of Carcinogenesis and Cancer Invasion (Fudan University), Ministry of Education, Shanghai, 200032, China.
2. Cancer Research Institute, Central South University
Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Changsha, 410078, China.
3. Institute of Biomedical Sciences, Fudan University, Shanghai, 200032, China.
4. State Key Laboratory of Genetic Engineering Fudan University, Shanghai, 200433, China.
# co-first authors

Citation:
Huang A, Zhang X, Zhou SL, Cao Y, Huang XW, Fan J, Yang XR, Zhou J. Plasma Circulating Cell-free DNA Integrity as a Promising Biomarker for Diagnosis and Surveillance in Patients with Hepatocellular Carcinoma. J Cancer 2016; 7(13):1798-1803. doi:10.7150/jca.15618. https://www.jcancer.org/v07p1798.htm
Other styles

File import instruction

Abstract

The clinical significance of circulating cell-free DNA (cfDNA) integrity as diagnostic and surveillance biomarker in hepatocellular carcinoma (HCC) was investigated and compared to that of alpha fetoprotein (AFP). Liver cancer patients had lower cfDNA integrity than those with benign diseases (P = 0.0167) and healthy individuals (P = 0.0025). Patients with HCC and non-HCC liver cancers (P = 0.7356), and patients with benign diseases and healthy individuals (P = 0.9138) had comparable cfDNA integrity respectively. cfDNA integrity increased after hepatectomy in cancer patients (P = 0.0003). The AUCs for detecting HCC by cfDNA integrity and AFP were 0.705 (P = 0.005) and 0.605 (P = 0.156), respectively. We found cfDNA integrity decreased in HCC patients and has the potential as promising biomarker for HCC diagnosis and treatment surveillance.

Keywords: circulating cell-free DNA, cfDNA, integrity, hepatocellular carcinoma.


Citation styles

APA
Huang, A., Zhang, X., Zhou, S.L., Cao, Y., Huang, X.W., Fan, J., Yang, X.R., Zhou, J. (2016). Plasma Circulating Cell-free DNA Integrity as a Promising Biomarker for Diagnosis and Surveillance in Patients with Hepatocellular Carcinoma. Journal of Cancer, 7(13), 1798-1803. https://doi.org/10.7150/jca.15618.

ACS
Huang, A.; Zhang, X.; Zhou, S.L.; Cao, Y.; Huang, X.W.; Fan, J.; Yang, X.R.; Zhou, J. Plasma Circulating Cell-free DNA Integrity as a Promising Biomarker for Diagnosis and Surveillance in Patients with Hepatocellular Carcinoma. J. Cancer 2016, 7 (13), 1798-1803. DOI: 10.7150/jca.15618.

NLM
Huang A, Zhang X, Zhou SL, Cao Y, Huang XW, Fan J, Yang XR, Zhou J. Plasma Circulating Cell-free DNA Integrity as a Promising Biomarker for Diagnosis and Surveillance in Patients with Hepatocellular Carcinoma. J Cancer 2016; 7(13):1798-1803. doi:10.7150/jca.15618. https://www.jcancer.org/v07p1798.htm

CSE
Huang A, Zhang X, Zhou SL, Cao Y, Huang XW, Fan J, Yang XR, Zhou J. 2016. Plasma Circulating Cell-free DNA Integrity as a Promising Biomarker for Diagnosis and Surveillance in Patients with Hepatocellular Carcinoma. J Cancer. 7(13):1798-1803.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) License. See http://ivyspring.com/terms for full terms and conditions.
Popup Image